Loading GATECHDVR price...
Peers are the listed companies in the exchange's own industry group: Other Financial Services. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to March 2026 (results filed 29 May 2026), sales rose 23.9% from a year earlier to Rs 6.0 cr and profit fell 5.2% to Rs 1.7 cr.
- Operating margin rose from 4.8% in FY23 to 58.4% in FY26.
- No borrowings at the FY26 balance sheet.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 20 results, the share rose on 8 and fell on 12, and moved by 3% or more on 11.
Q4 FY26: results filed 29 May 2026. The share went from its close on 27 May 2026 to its close on 1 Jun 2026 0.00%.
Of every Rs 100 of sales in FY26, Rs 42 went on running costs, Rs 23 on depreciation and Rs 1.4 on tax; Rs 39 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | 395% | -27.9% | 82.7% | 59.9% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | -543% | 4.8% | 32.0% | 43.8% | 58.4% |
| Net marginProfit after everything, per Rs 100 of sales. | -381% | -12.5% | 14.7% | 29.9% | 39.3% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | 19.4% | 15.9% | 8.3% | 8.0% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | -1.0% | 10.9% | 8.7% | 7.7% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | - | 1.24x | 0.00x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | -12.3x | -0.2x | 2.8x | 18.0x | - |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 132 Cr of assets. Its owners funded 82% of that, with no borrowings.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 3 Cr, spent Rs 39 Cr on plant and equipment, and cash rose by Rs 0 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CRISIL Crisil Limited | 34,926 cr | 39.0x | 10.7x | 27.4% | - | 0.00 | 20.8% | +20.2% | 1.24% |
| KISSHT OnEMI Technology Solutions Limited | 5,140 cr | - | 3.8x | - | 32.9% | 0.81 | - | - | 0.00% |
| GYFTR Gyftr Limited | 1,229 cr | - | - | - | - | - | - | - | - |
| PRIMESECU Prime Securities Limited | 929 cr | 174.4x | 3.6x | 1.8% | - | - | 3.7% | -27.1% | 0.54% |
| WEALTH Wealth First Portfolio Managers Limited | 890 cr | 26.9x | 5.9x | 19.2% | 30.3% | 0.00 | 56.6% | -42.3% | 2.00% |
| CENTRUM Centrum Capital Limited | 860 cr | - | 2.8x | -24.5% | 14.7% | 12.19 | -8.9% | +7.8% | 0.00% |
| THEINVEST The Investment Trust Of India Limited | 445 cr | 13.3x | 0.6x | 5.0% | 8.8% | 0.07 | 13.5% | -15.3% | 0.00% |
| NDLVENTURE NDL Ventures Limited | 371 cr | - | 6.3x | - | 2.0% | 0.00 | - | - | 0.45% |
| MAHAPEXLTD Maha Rashtra Apex Corporation Limited | 131 cr | - | 0.3x | - | 0.6% | 0.00 | - | +12.1% | 0.00% |
| RELIABLE Reliable Data Services Limited | 129 cr | 14.3x | 1.8x | 10.5% | 13.1% | 0.29 | 4.4% | +45.9% | 0.00% |
| GATECH GACM Technologies Limited | 67 cr | 10.4x | 0.6x | 6.4% | 7.7% | 0.00 | 35.0% | -32.8% | 0.00% |
| GATECHDVR GACM Technologies Limited | 53 cr | 5.9x | 0.5x | 8.0% | 7.7% | 0.00 | 39.3% | +23.9% | 0.00% |
| GLFL Gujarat Lease Financing Limited | 14 cr | - | - | - | 0.8% | - | - | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from -542.9% to 58.4% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
| Date | Party | Side | Qty | Price | Value |
|---|---|---|---|---|---|
| 2026-07-30 | ANKITA VISHAL SHAH | BUY | 21,98,863 | 0.5 | Rs 0.11 Cr |
| 2026-07-30 | ANKITA VISHAL SHAH | SELL | 21,26,916 | 0.49 | Rs 0.1 Cr |
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.